# Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia

> **NCT01380756** · PHASE1 · COMPLETED · sponsor: **Amgen** · enrollment: 35 (actual)

## Conditions studied

- Cancer
- Hematologic Malignancies
- Leukemia
- Myeloid Leukemia

## Interventions

- **DRUG:** Arm 1- Dose Escalation
- **DRUG:** Arm 2- Dose Expansion

## Key facts

- **NCT ID:** NCT01380756
- **Lead sponsor:** Amgen
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-10-04
- **Primary completion:** 2014-09-04
- **Final completion:** 2014-09-04
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2017-11-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01380756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01380756, "Study Evaluating Orally Administered AMG 900 in Adult Subjects With Acute Myeloid Leukemia". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT01380756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*